These results further suggested that the PI3K/AKT/mTOR signaling pathway may be implicated in ccRCC initiation and progression, and that components could be used as potential therapeutic targets in ccRCC. The gene discussed is PIK3CD; the disease is nonpapillary renal cell carcinoma.